Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01419691 · ClinicalTrials.gov registry record · Phase 2
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01419691 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT01419691, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
Interventions
- DRUG auranofin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01419691
The ClinicalTrials.gov registry entry for NCT01419691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which auranofin is the first listed.
NCT01419691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01419691 about?
NCT01419691 is a clinical study titled "Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).
What is the current status of trial NCT01419691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2011-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01419691?
The interventions under investigation include: auranofin (DRUG).
Who is sponsoring clinical trial NCT01419691?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.